STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #732 by analyst upside · 2026-08-12
PRME
Prime Medicine, Inc.
Healthcare · Market Cap $591M · P/E 0x
ANALYST PRICE TARGET
+115.6%
implied upside to consensus target
Current Price $3.26
Consensus Target $7.03
Bull Target $11.0
Bear Target $4.25
Analysts Covering 9
ANALYST CONSENSUS - BUY
Strong Buy
1
Buy
6
Hold
2
Sell
0
52-Week Low $2.67
52-Week High $6.94
YTD Return -7.6%
FUNDAMENTALS
Market Cap $591M
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-1.05
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $4M
Profit Margin N/A
52-WEEK RANGE
52-Week Low $2.67
52-Week High $6.94
Current Price $3.26
Bear Target $4.25
Bull Target $11.0
● Now $3.26 ● Target $7.03
TRADING DATA
Avg Volume 3.4M
YTD Return -7.6%
Analyst Count 9
Consensus Buy
Upside to Target +115.6%
Last Updated 2026-08-12

ANALYST SUMMARY

Prime Medicine, Inc. (PRME) is currently trading at $3.26 with a Wall Street consensus price target of $7.03, implying potential upside of 115.6% over the next 12 months. 9 analysts currently cover PRME, with a consensus rating of Buy - 78% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $11.0, while the most cautious has a target of $4.25.

PRME operates in the Healthcare sector with a market capitalisation of $591M. The stock is down 7.6% year-to-date and is currently trading near the lower end of its 52-week range of $2.67 – $6.94.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for PRME, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Oppenheimer ● Initiated
Outperform 2026-03-12 14% win rate (7 calls)
LifeSci Capital ● Initiated
Outperform 2025-12-23 Building track record
Citigroup - Reiterated
Neutral → Neutral 2025-11-11 Building track record
Chardan Capital - Reiterated
Buy → Buy 2025-11-10 33% win rate (6 calls)
Citigroup - Reiterated
Neutral → Neutral 2025-08-12 Building track record
Chardan Capital - Reiterated
Buy → Buy 2025-08-08 33% win rate (6 calls)
Citigroup ↓ Downgrade
Buy → Neutral 2025-05-27 Building track record
JMP Securities - Reiterated
Market Outperform → Market Outperform 2025-05-20 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
32
out of 100
Coverage depth
18/30
Consensus clarity
0/30
Vote unanimity
12/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →